Ketamine and depression: a narrative review
Drug Design, Development and Therapy August 1, 2019 Alexandrine Corriger, G. Pickering 197 citations
Abstract Depression is the third leading cause of disability in the world. Depressive symptoms may be reduced within several weeks after the start of conventional antidepressants, but treatment resistance concerns one-third of patients who fail to achieve recovery. Over the last 20 years, ketamine, an antagonist of the N-methyl-D-aspartate receptor, has been described to have antidepressant...